Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

 | Nov 02, 2017 | 9:35 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

nbix

,

trvn

,

ntla

Shares of Neurocrine Biosciences Inc. (NBIX) jumped 19.8% to $73 ahead of the market open on Thursday, Nov. 2, following the release of the San Diego firm's third-quarter results after the market close on Wednesday.

The company had a net loss of $11.1 million, or $0.13 per share, compared to a net loss of $36.9 million, or $0.43 per share, in the year-ago period. Net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The U.S. Food and Drug Administration approved Ingrezza in April.

Meanwhile, shares of Trevena Inc. (TRVN) rose 7.6% to $1.55 after the Chesterbrook, Pa.-based company said it has recently submitted a new drug application for pain management drug Olinvo (oliceridine injection) to the FDA.

Olinvo is an analgesic for the management of moderate-to-severe acute pain in the hospital and similar settings. The FDA granted breakthrough therapy designation to Olinvo in February of last year.

Other biotech stock movers include Intellia Therapeutics Inc. (NTLA) . Shares were down 11.9% to $22.44 after the Cambridge, Mass.-based firm on Wednesday priced its underwritten public offering of 6.25 million shares at $24 apiece, which would generate gross proceeds of $150 million. The company has also given underwriters a 30-day option to purchase up to an additional 937,500 shares.

Columnist Conversations

Looking like a tough open, but not as brutal as you would expect after Tuesday.
If the slide in the chip space doesn't halt off Texas Instruments' (TXN) good guidance tomorrow, raise cash a...
Today is another day that proves that shorting puts naked is beyond ignorant and the worst way I know to lear...
The SPX has the 200 DMA @ 2607 The 4/2 low @ 2553.80 The 2/9 low @ 2532.69 below   I do WANT TO BE A ...

BEST IDEAS

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.